On July 18, 2019 NovImmune reported that it is excited to be launching the all new company website and branding (Press release, Light Chain Bioscience, JUL 18, 2019, View Source [SID1234573675]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the successful divestment of EmaCo AG, a newly established company owning emapalumab and related assets to Sobi on 18 July 2019, NovImmune underwent major rebranding activities.

NovImmune SA will continue the successful legacy of 20+ years of antibody expertise and focus on its bispecific technology and associated programs and will rebrand as:

«Light Chain Bioscience – A brand of Novimmune SA»

The brand Light Chain Bioscience brings to life the research and development of novel multi-specific antibodies that rely on their light chain for their function.

A key distinctive feature of these multispecific antibodies is their native human structure, making them well tolerated and easy to develop.